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1,2,4-TriazoleAbstract In an effort to develop novel antiamoebic scaffolds having better efficacy than the stan-
dard drug metronidazole (IC50 = 1.80 lM) used against Entamoeba histolytica, quinazolin-4(3H)-
one Schiff base conjugates were synthesized and evaluated against HM1: IMSS strain of E. histolyt-
ica. Out of the thirteen compounds (S2-S14), six compounds (S2, S3, S4, S5, S6 and S11) were
found to be better inhibitors than metronidazole and showed low cytotoxicity on HeLa cells, a cer-
vical cancer cell line. The structure of intermediate compound S1 was confirmed by crystal structure
studies.
 2016 Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Amebiasis, caused by gastrointestinal protozoan Entamoeba
histolytica is the third principal cause of death among parasitic
diseases worldwide. Its prevalence is greatest in the countries
with poor sanitation, poverty, ignorance, and malnutrition
[1–3]. It is estimated to result in 110,000 deaths and more than500 million people get infected annually [4]. E. histolytica is
primarily found in the colon as inactive, but after certain per-
iod it becomes lethal to human being by causing severe compli-
cations like dysentery, colitis and liver abscess [5–7]. Amoebic
colitis characterized by ulceration and inflammation of the
colon and amoebic liver abscesses are the two major clinical
features of E. histolytica infection. Amoebic colitis when
accompanied with extreme gut inflammation can closely mimic
inflammatory bowel disease [8,9]. Therefore it is important to
identify and treat amebiasis appropriately. Although the avail-
ability of a large number of antibacterial agents for clinical
treatment has proved propitious for the health status of man-
kind [10]. The existence of antimicrobial resistance for the past
few years has threatened their therapeutic utility thereby,
exhibiting severe global crisis [11–14]. The antiamoebic drugamoebic
2 S. Tariq et al.metronidazole is the treatment of choice for this disease but
certain side effects [15–18] such as neurologic toxicity [19],
genotoxicity, carcinogenicity [18,20,21] spermatozoid damage
[22] are associated with it. Moreover resistance of E. histolytica
to metronidazole and recurrence of intestinal and hepatic ame-
biasis have been reported [23,24]. This situation has necessi-
tated the development of novel anti-amoebic agents with
increased efficacy and lesser toxicity for the host [25]. Because
of their high therapeutic index and clinical utility, quinazolin-4
(3H)-one and its derivatives are promising scaffolds for the
synthesis of potential bioactive agents [26]. Quinazolin-4-
(3H)-ones and 1,2,4-triazoles exhibited a diverse range of
bioactivities such as analgesic [27,28], anti-inflammatory
[29,30], anti-tumour [31,32], anticancer [33–35], antibacterial
[36–38] and anticonvulsant [39–41] therefore, these two impor-
tant heterocyclic scaffolds have been incorporated into a wide
variety of interesting molecules to transform them into better
drugs. Due to the important and versatile biological activities,
Schiff bases [42] can be used as ideal lead structures in drug
development. Therefore, we synthesized quinazolin-4(3H)-
one Schiff base conjugates with the aim to develop compounds
with enhanced antiamoebic efficacy than the standard drug
metronidazole [25]. To the best of our knowledge, this is the
first report of quinazolin-4-(3H)-one derivatives showing
promising antiamoebic activity against E. histolytica.
2. Experimental
2.1. Materials and measurements
All the required chemicals were purchased from Merck and
Aldrich Chemical Company (USA). Precoated aluminium
sheets (Silica gel 60 F254, Merck Germany) were used for
thin-layer chromatography (TLC) and spots were visualized
under UV light. The melting points were recorded on Veego
instrument with model specifications REC-22038 A2 and are
uncorrected. Elemental analyses were performed on Elementar
Vario analyser and the results are within ±0.4% of the theo-
retical values. IR spectra (KBr) were acquired at Bruker FT-
IR spectrophotometer. 1H and 13C NMR were recorded on a
Bruker Spectrospin DPX 400 MHz and Bruker Spectrospin
DPX 75 MHz spectrometer respectively, using DMSO-d6 as
a solvent and trimethylsilane (TMS) as the internal standard.
Splitting patterns are designated as follows; s, singlet; d, dou-
blet; t, triplet; m, multiplet. Chemical shift values are given in
ppm. Mass spectra were recorded by ESI-MS (AB-Sciex 2000,
Applied Biosystem).
2.2. General procedure for the synthesis of methyl 2-(2-
chloroacetamido)benzoate (S)
An aromatic amine (0.12 mol) was dissolved in glacial acetic
acid and saturated solution of sodium acetate. The mixture
was warmed and then cooled in ice bath with stirring. To this
solution was added drop wise a solution of chloro acetyl chlo-
ride (0.12 mol). The progress of the reaction was monitored by
thin layer chromatography. After half an hour white product
was formed. This was separated, filtered, washed with cold
water and purified by crystallization from aqueous alcohol [43].
White solid; Yield: 90%; mp: 118 C; Anal. Calc. (%) for
C10H10ClNO3: C, 52.76; H, 4.43; Cl, 15.57; N, 6.15; O, 21.08;Please cite this article in press as: S. Tariq et al., Design, synthesis and biological eva
agents, Journal of Saudi Chemical Society (2016), http://dx.doi.org/10.1016/j.jscs.2found: C, 52.78; H, 4.41; Cl, 15.59; N, 6.14; O, 21.07; 1H
NMR (DMSO-d6) d (ppm): 11.31 (s, 1H, NH), 8.39 (d, 1H,
J= 8.4 Hz, Ar-H), 7.99 (d, 1H, J= 8.4 Hz, Ar-H), 7.67–7.63
(m, 1H, Ar-H), 7.27 (t, 1H, J= 7.5 Hz, Ar-H), 4.44 (s, 2H,
CH2), 3.90 (s, 3H, OCH3); ESI-MS: m/z= 229 (M
++1).
2.3. Synthesis of methyl 2-(2-(1H-1,2,4-triazol-1-yl)acetamido)
benzoate (S0)
Methyl 2-(2-chloroacetamido)benzoate (S) (0.1 mol) was trea-
ted with (0.1 mol) commercially available 1,2,4 triazole in the
presence of (0.05 mol) K2CO3 in dimethylformamide under
reflux for 18 h to afford methyl 2-(2-(1H-1,2,4-triazol-1-yl)acet
amido)benzoate.
White solid; Yield: 92%; mp: 102 C; Anal. Calc. (%) for
C12H12N4O3: C, 55.38; H, 4.65; N, 21.53; O, 18.44; found:
C, 55.39; H, 4.64; N, 21.52; O, 18.43; 1H NMR (DMSO-d6)
d (ppm): 10.68 (s, 1H, NH), 8.59 (s, 1H, Ar-H), 8.17 (d, 1H,
J= 7.8 Hz, Ar-H), 8.05 (s, 1H, Ar-H), 7.92 (d, 1H,
J= 7.8 Hz, Ar-H), 7.64 (t, 1H, J= 7.2 Hz, Ar-H), 7.26
(t, 1H, J= 7.2 Hz, Ar-H), 5.24 (s, 2H, CH2), 3.82 (s, 3H,
OCH3);
13C NMR (DMSO-d6) d (ppm): 167.67, 165.71,
152.31, 146.15, 138.98, 134.41, 131.08, 124.52, 122.11, 119.17,
61.72, 52.67; ESI-MS: m/z= 261 (M++1).
2.4. Synthesis of 2-((1H-1,2,4-triazol-1-yl)methyl)-3-
aminoquinazolin-4(3H)-one (S1)
Methyl 2-(2-(1H-1,2,4-triazol-1-yl)acetamido)benzoate (S0)
(0.1 mol) was reacted with hydrazine hydrate (0.3 mol) in etha-
nol under reflux for 12 h to give 2-((1H-1,2,4-triazol-1-yl)
methyl)-3-aminoquinazolin-4(3H)-one.
Yellow solid; Yield: 92%; mp: 66 C; Anal. Calc. (%) for
C11H10N6O: C, 54.54; H, 4.16; N, 34.69; O, 6.60; found: C,
54.55; H, 4.14; N, 34.68; O, 6.61; FT-IR mmax (cm
1): 3477
(NH2),
1H NMR (DMSO-d6) d (ppm): 8.64 (s, 1H, Ar-H),
8.16 (d, 1H, J= 7.8 Hz, Ar-H), 8.03 (s, 1H, Ar-H), 7.80
(t, 1H, J= 6.9 Hz, Ar-H), 7.56 (m, 2H, Ar-H), 5.76 (s, 2H,
CH2), 5.69 (s, 2H, NH2),
13C NMR (DMSO-d6) d (ppm):
161.00, 153.29, 151.68, 146.54, 146.31, 134.79, 127.62, 127.35,
126.47, 120.70, 50.63; ESI-MS: m/z= 265 (M++23).
2.5. Synthesis of Schiff bases derived from 2-((1H-1,2,4-triazol-
1-yl)methyl)-3-aminoquinazolin-4(3H)-one (S2-S14)
An equimolar mixture of compound S1 (0.01 mol) and substi-
tuted aldehydes (0.01 mol) in absolute ethanol (10 mL) was
allowed to reflux for 2–4 h, H2SO4 (0.5 mL) was added slowly
to the reaction mixture and progress of the reaction was mon-
itored through thin layer chromatography. When the reaction
was completed, it was allowed to cool to attain room temper-
ature. The solid crystalline product was separated out on
standing. The solid product was filtered, dried and crystallized
from methanol to give title compounds in good yields.
2.5.1. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-(2-
chlorobenzylideneamino)quinazolin-4(3H)-one (S2)
Yield: 82.5%; mp: 115 C; Anal. Calc. (%) for C18H13ClN6O:
C, 59.27; H, 3.59; Cl, 9.72; N, 23.04; O, 4.39; found: C, 59.25;
H, 3.58; Cl, 9.70; N, 23.06; O, 4.37; FT-IR mmax (cm
1): 1687
(C‚O), 1610 (C‚N); 1H NMR (DMSO-d6) d (ppm): 9.51luation of quinazolin-4(3H)-one Schiﬀ base conjugates as potential antiamoebic
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Quinazolin-4(3H)-one Schiff base conjugates as antiamoebic agents 3(s, 1H, CH‚N), 8.61 (s, 1H, Ar-H), 8.26–8.20 (m, 2H, Ar-H),
8.01 (s, 1H, Ar-H), 7.87 (t, 1H, J= 7.7 Hz, Ar-H), 7.66–7.62
(m, 2H, Ar-H), 7.60–7.55 (m, 3H, Ar-H), 5.78 (s, 2H, CH2);
13C NMR (DMSO-d6) d (ppm): 163.56, 158.30, 151.10,
150.66, 145.87, 145.74, 135.70, 135.35, 134.73, 130.82, 130.20,
128.67, 128.42, 127.92, 127.79, 127.43, 121.85, 51.46; ESI-
MS: m/z= 365 (M++1).
2.5.2. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-(3-
chlorobenzylideneamino)quinazolin-4(3H)-one (S3)
Yield: 85%; mp: 131 C; Anal. Calc. (%) for C18H13ClN6O: C,
59.27; H, 3.59; Cl, 9.72; N, 23.04; O, 4.39; found: C, 59.25; H,
3.57; Cl, 9.72; N, 23.08; O, 4.35; FT-IR mmax (cm
1): 1676
(C‚O), 1606 (C‚N); 1H NMR (DMSO-d6) d (ppm): 9.12
(s, 1H, CH‚N), 8.62 (s, 1H, Ar-H), 8.21 (d, 1H,
J= 7.8 Hz, Ar-H), 8.06 (s, 1H, Ar-H), 8.01 (s, 1H, Ar-H),
7.93 (d, 1H, J= 7.2 Hz, Ar-H), 7.87 (t, 1H, J= 7.5 Hz, Ar-
H), 7.63 (d, 1H, J= 7.8 Hz, Ar-H), 7.60–7.57 (m, 3H, Ar-
H), 5.76 (s, 2H, CH2);
13C NMR (DMSO-d6) d (ppm):
167.01, 157.98, 151.55, 150.64, 145.95, 145.82, 135.31, 134.90,
134.42, 132.90, 131.49, 128.38, 128.29, 127.91, 127.82, 127.31,
121.72, 51.37; ESI-MS: m/z= 365 (M++1).
2.5.3. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-(4-
chlorobenzylideneamino)quinazolin-4(3H)-one (S4)
Yield: 85%; mp: 120 C; Anal. Calc. (%) for C18H13ClN6O: C,
59.27; H, 3.59; Cl, 9.72; N, 23.04; O, 4.39; found: C, 59.24; H,
3.56; Cl, 9.71; N, 23.07; O, 4.36; FT-IR mmax (cm
1): 1677
(C‚O), 1604 (C‚N); 1H NMR (DMSO-d6) d (ppm): 9.09
(s, 1H, CH‚N), 8.61 (s, 1H, Ar-H), 8.20 (d, 1H,
J= 7.5 Hz, Ar-H), 7.44 (d, 3H, J= 7.4 Hz, Ar-H), 7.86 (t,
1H, J= 7.3 Hz, Ar-H), 7.67 (d, 2H, J= 8.4 Hz, Ar-H), 7.61
(t, 2H, J= 8.8 Hz, Ar-H), 5.75 (s, 2H, CH2);
13C NMR
(DMSO-d6) d (ppm): 167.55, 157.97, 151.32, 150.54, 145.86,
137.98, 135.29, 131.67, 131.03, 129.77, 127.91, 127.82, 127.30,
121.74, 51.42; ESI-MS: m/z= 365 (M++1).
2.5.4. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-(4-
nitrobenzylideneamino)quinazolin-4(3H)-one (S5)
Yield: 78%; mp: 109 C; Anal. Calc. (%) for C18H13N7O3: C,
57.60; H, 3.49; N, 26.12; O, 12.79; found: C, 57.61; H, 3.48; N,
26.10; O, 12.78; FT-IR mmax (cm
1): 1676 (C‚O), 1614
(C‚N); 1H NMR (DMSO-d6) d (ppm): 9.36 (s, 1H, CH‚N),
8.62 (s, 1H, Ar-H), 8.40 (d, 2H, J= 8.4 Hz, Ar-H), 8.25 (t, 3H,
J= 8.7 Hz, Ar-H), 8.00 (s, 1H, Ar-H), 7.85–7.68 (m, 1H, Ar-
H), 7.59 (d, 2H, J= 8.1 Hz, Ar-H), 5.80 (s, 2H, CH2);
13C
NMR (DMSO-d6) d (ppm) 165.73, 158.13, 151.88, 150.79,
150.14, 146.07, 145.81, 138.74, 135.53, 130.49, 128.10, 127.93,
127.45, 124.71, 121.80, 51.41; ESI-MS: m/z= 376 (M++1).
2.5.5. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-(furan-2-
ylmethyleneamino)quinazolin-4(3H)-one (S6)
Yield: 91%; mp: 194 C; Anal. Calc. (%) for C16H12N6O2: C,
60.00; H, 3.78; N, 26.24; O, 9.99; found: C, 60.01; H, 3.79; N,
26.25; O, 9.97; FT-IR mmax (cm
1): 1669 (C‚O), 1600 (C‚N);
1H NMR (DMSO-d6) d (ppm): 8.89 (s, 1H, CH‚N), 8.59 (s,
1H, Ar-H), 8.19 (d, 2H, J= 7.5 Hz, Ar-H), 7.99 (s, 1H, Ar-
H), 7.86 (t, 1H, J= 7.5 Hz, Ar-H), 7.61 (t, 2H, J= 7.8 Hz,
Ar-H), 7.37 (s, 1H, Ar-H), 6.82 (s, 1H, Ar-H), 5.68 (s, 2H,Please cite this article in press as: S. Tariq et al., Design, synthesis and biological eva
agents, Journal of Saudi Chemical Society (2016), http://dx.doi.org/10.1016/j.jscs.2CH2);
13C NMR (DMSO-d6) d (ppm): 158.04, 156.98,
151.82, 150.54, 148.71, 147.88, 146.20, 145.87, 135.16, 127.78,
127.24, 121.73, 121.13, 113.51, 51.22; ESI-MS: m/z= 321
(M++1).
2.5.6. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-(2,5-
dimethoxybenzylideneamino)quinazolin-4(3H)-one (S7)
Yield: 91%; mp: 194 C; Anal. Calc. (%) for C20H18N6O3: C,
61.53; H, 4.65; N, 21.53; O, 12.29; found: C, 61.51; H, 4.62; N,
21.52; O, 12.28; FT-IR mmax (cm
1): 1682 (C‚O), 1606
(C‚N); 1H NMR (DMSO-d6) d (ppm): 9.21 (s, 1H, CH‚N),
8.63 (s, 1H, Ar-H), 8.20 (d, 1H, J= 7.2 Hz, Ar-H), 8.03 (s,
1H, Ar-H), 7.85 (t, 1H, J= 7.8 Hz, Ar-H), 7.60–7.43 (m,
3H, Ar-H), 7.24–7.21 (m, 1H, Ar-H), 7.17 (d, 1H,
J= 9.0 Hz, Ar-H), 5.68 (s, 2H, CH2), 3.83 (s, 3H, OCH3),
3.81 (s, 3H, OCH3);
13C NMR (DMSO-d6) d (ppm): 163.65,
158.12, 154.44, 153.71, 151.01, 150.49, 145.89, 135.13, 127.77,
127.31, 121.87, 121.79, 120.90, 114.30, 110.27, 56.88, 56.12,
51.61; ESI-MS: m/z= 391 (M++1).
2.5.7. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-(4-
methoxybenzylideneamino)quinazolin-4(3H)-one (S8)
Yield: 88%; mp: 125 C; Anal. Calc. (%) for C19H16N6O2: C,
63.32; H, 4.48; N, 23.32; O, 8.88; found: C, 63.31; H, 4.49; N,
23.31; O, 8.89; FT-IR mmax (cm
1): 1674 (C‚O), 1599 (C‚N);
1H NMR (DMSO-d6) d (ppm): 9.27 (s, 1H, CH‚N), 8.31 (s,
1H, Ar-H), 8.21 (d, 1H, J= 7.8 Hz, Ar-H), 8.07 (d, 2H,
J= 8.4 Hz, Ar-H), 7.83 (t, 1H, J= 7.5 Hz, Ar-H), 7.70 (d,
2H, J= 8.2 Hz, Ar-H), 7.60 (t, 2H, J= 7.5 Hz, Ar-H), 7.52
(d, 1H, J= 8.0 Hz, Ar-H), 5.63 (s, 2H, CH2), 3.32 (s, 3H,
OCH3);
13C NMR (DMSO-d6) d: 168.94, 163.47, 158.00,
151.74, 150.57, 146.00, 135.07, 131.41, 127.77, 127.19, 125.14,
121.79, 115.08, 56.04, 51.29; ESI-MS: m/z= 361 (M++1).
2.5.8. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-
(benzylideneamino)quinazolin-4(3H)-one (S9)
Yield: 82%; mp: 110 C; Anal. Calc. (%) for C18H14N6O: C,
65.44; H, 4.27; N, 25.44; O, 4.84; found: C, 65.42; H, 4.25;
N, 25.46; O, 4.85; FT-IR mmax (cm
1): 1682 (C‚O), 1612
(C‚N); 1H NMR (DMSO-d6) d (ppm): 9.03 (s, 1H, CH‚N),
8.59 (s, 1H, Ar-H), 8.21 (d, 1H, J= 7.5 Hz, Ar-H), 7.99 (s,
1H, Ar-H), 7.95 (d, 2H, J= 7.2 Hz, Ar-H), 7.87 (t, 1H,
J= 7.7 Hz, Ar-H), 7.65–7.58 (m, 5H, Ar-H), 5.74 (s, 2H,
CH2);
13C NMR (DMSO-d6) d (ppm): 169.16, 157.97,
151.84, 150.61, 146.04, 145.95, 135.21, 133.34, 132.72, 129.60,
129.40, 127.83, 127.28, 121.79, 51.27; ESI-MS: m/z= 331
(M++1).
2.5.9. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-((1H-indol-3-
yl)methyleneamino)quinazolin-4(3H)-one (S10)
Yield: 87%; mp: 151 C; Anal. Calc. (%) for C20H15N7O: C,
65.03; H, 4.09; N, 26.54; O, 4.33; found: C, 65.01; H, 4.08;
N, 26.53; O, 4.32; FT-IR mmax (cm
1): 1667 (C‚O), 1603
(C‚N); 1H NMR (DMSO-d6) d (ppm): 12.08 (s, 1H, NH)
8.91 (s, 1H, CH‚N), 8.75 (s, 1H, Ar-H), 8.26–8.12 (m, 4H,
Ar-H), 7.85 (t, 1H, J= 7.5 Hz, Ar-H), 7.60 (t, 3H,
J= 8.4 Hz, Ar-H), 7.33–7.25 (m, 2H, Ar-H), 5.81 (s, 2H,
CH2);
13C NMR (DMSO-d6) d (ppm): 165.85, 158.26,
150.94, 150.63, 146.11, 145.89, 137.88, 136.31, 134.80, 127.71,luation of quinazolin-4(3H)-one Schiﬀ base conjugates as potential antiamoebic
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Table 1 Crystal data and structure refinement for the
compound 3-amino-2-(1H-1,2,4-triazol-1-ylmethyl)quinazolin-
4(3H)-one (S1).
S1
Formula C11H10N6O
Formula weight 242.25
T (K) 100(2)
Wavelength (A˚) 0.71073
Crystal system Monoclinic
Space group P21/c
a (A˚) 4.63170(10)
b (A˚) 18.4777(5)
c (A˚) 12.4608(4)
b () 98.441(2)
V (A˚3) 1054.88(5)
Z 4
F000 504
Dcalc (g cm
3) 1.525
l (mm1) 0.107
h () 1.99–26.38
Rint 0.0300
Crystal size (mm3) 0.50  0.41  0.30
Goodness-of-fit on F2 1.161
R1[I> 2r(I)]
a 0.0351
wR2 (all data)
b 0.1310
a R1 = R||Fo|  |Fc||/R|Fo|.
b wR2 = {R[w(||Fo|
2  |Fc|2|)2]/R[w(Fo2)2]}1/2.
4 S. Tariq et al.127.51, 127.08, 124.69, 123.79, 122.59, 122.16, 121.93, 112.87,
110.68, 51.39; ESI-MS: m/z= 370 (M++1).
2.5.10. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-((3-
methylthiophen-2-yl)methyleneamino)quinazolin-4(3H)-one
(S11)
Yield: 91%; mp: 194 C; Anal. Calc. (%) for C17H14N6OS: C,
58.27; H, 4.03; N, 23.98; O, 4.57; S, 9.15; found: C, 58.25; H,
4.01; N, 23.99; O, 4.56; S, 9.16; FT-IR mmax (cm
1): 1671
(C‚O), 1599 (C‚N); 1H NMR (DMSO-d6) d (ppm): 9.17
(s, 1H, CH‚N), 8.65 (s, 1H, Ar-H), 8.20 (d, 1H,
J= 7.5 Hz, Ar-H), 8.06 (s, 1H, Ar-H), 7.91–7.75 (m, 2H,
Ar-H), 7.61–7.55 (m, 2H, Ar-H), 7.13–7.11 (m, 1H, Ar-H),
5.66 (s, 2H, CH2), 2.27 (s, 3H, CH3);
13C NMR (DMSO-d6)
d (ppm): 162.97, 158.07, 151.38, 150.25, 146.63, 145.96,
135.07, 132.96, 131.96, 130.56, 127.76, 127.71, 127.25, 121.76,
51.24, 14.37; ESI-MS: m/z= 351 (M++1).
2.5.11. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-(2-
methylbenzylideneamino)quinazolin-4(3H)-one (S12)
Yield: 85%; mp: 119 C; Anal. Calc. (%) for C19H16N6O: C,
66.27; H, 4.68; N, 24.40; O, 4.65; found: C, 66.28; H, 4.69;
N, 24.41; O, 4.62; FT-IR mmax (cm
1): 1681 (C‚O), 1605
(C‚N); 1H NMR (DMSO-d6) d (ppm): 8.94 (s, 1H, CH‚N),
8.58 (s, 1H, Ar-H), 8.20 (d, 1H, J= 7.2 Hz, Ar-H), 7.98 (s,
1H, Ar-H), 7.85 (d, 3H, J= 6.9 Hz, Ar-H), 7.61–7.56 (m,
2H, Ar-H), 7.40 (d, 2H, J= 7.2 Hz, Ar-H), 5.74 (s, 2H,
CH2), 2.50 (s, 3H, CH3);
13C NMR (DMSO-d6) d (ppm):
169.13, 157.99, 151.82, 150.58, 146.01, 145.98, 143.71, 135.15,
130.19, 130.04, 129.41, 127.80, 127.46, 127.25, 123.64, 121.81,
117.72, 51.30, 21.77; ESI-MS: m/z= 345 (M++1).
2.5.12. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-(4-
(dimethylamino)benzylideneamino)quinazolin-4(3H)-one
(S13)
Yield: 81%; mp: 210 C; Anal. Calc. (%) for C20H19N7O: C,
64.33; H, 5.13; N, 26.26; O, 4.28; found: C, 64.31; H, 5.12;
N, 26.25; O, 4.27; FT-IR mmax (cm
1): 1672 (C‚O), 1597
(C‚N); 1H NMR (DMSO-d6) d (ppm): 8.62 (s, 1H, CH‚N),
8.56 (s, 1H, Ar-H), 8.17 (d, 1H, J= 7.8 Hz, Ar-H), 7.97 (s,
1H, Ar-H), 7.81–7.71 (m, 3H, Ar-H), 7.59–7.54 (m, 2H, Ar-
H), 6.83 (d, 2H, J= 8.7 Hz, Ar-H), 5.66 (s, 2H, CH2), 3.04
(s, 6H, 2CH3);
13C NMR (DMSO-d6) d (ppm): 169.48,
158.15, 153.73, 151.78, 150.67, 146.02, 134.86, 131.15, 127.74,
127.57, 127.10, 121.84, 119.26, 111.96, 51.27, 39.79; ESI-MS:
m/z= 374 (M++1).
2.5.13. (E)-2-((1H-1,2,4-Triazol-1-yl)methyl)-3-(benzo[d]
[1,3]dioxol-5-ylmethyleneamino)quinazolin-4(3H)-one (S14)
Yield: 91%; mp: 110 C; Anal. Calc. (%) for C19H14N6O3: C,
60.96; H, 3.77; N, 22.45; O, 12.82; found: C, 60.94; H, 3.75; N,
22.48; O, 12.81; FT-IR mmax (cm
1): 1667 (C‚O), 1608
(C‚N); 1H NMR (DMSO-d6) d (ppm): 8.86 (s, 1H, CH‚N),
8.60 (s, 1H, Ar-H), 8.18 (d, 1H, J= 8.1 Hz, Ar-H), 7.98 (s,
1H, Ar-H), 7.85–7.80 (t, 1H, J= 7.5 Hz, Ar-H), 7.60–7.52
(m, 3H, Ar-H), 7.40 (d, 1H, J= 8.1 Hz, Ar-H), 7.10 (d, 1H,
J= 8.1 Hz, Ar-H), 6.17 (s, 2H, Ar-H), 5.72 (s, 2H, CH2);
13C NMR(DMSO-d6) d (ppm): 168.38, 158.01, 151.90,
151.66, 150.60, 148.71, 145.94, 135.11, 127.77, 127.65, 127.21,
126.97, 121.76, 109.05, 106.31, 102.57, 51.37; ESI-MS:
m/z= 375 (M++1).Please cite this article in press as: S. Tariq et al., Design, synthesis and biological eva
agents, Journal of Saudi Chemical Society (2016), http://dx.doi.org/10.1016/j.jscs.22.6. X-ray crystal structure determination
Three-dimensional X-ray data were collected on a Bruker
Kappa Apex CCD diffractometer at low temperature for S1
by the /–x scan method. Reflections were measured from a
hemisphere of data collected from frames, each of them covering
0.3 in x. 13,269 reflections measured were corrected for
Lorentz and polarization effects and for absorption by multi-
scan methods based on symmetry-equivalent and repeated
reflections. Of them, 1834 independent reflections exceeded the
significance level (|F|/r|F|) > 4.0. After data collection, in each
case a multi-scan absorption correction (SADABS) [44] was
applied, and the structure was solved by direct methods and
refined by full matrix least-squares on F2 data using SHELX
suite of programs [45]. Hydrogen atoms were located in differ-
ence Fourier map and left to refine freely. Refinements were
done with allowance for thermal anisotropy of all non-
hydrogen atoms. A final difference Fourier map showed no
residual density in the crystal 0.243 and0.384 e.A˚3. Aweight-
ing scheme w= 1/[r2(Fo
2) + (0.086100 P)2 + 0.064000 P], was
used in the latter stages of refinement. Further details of the crys-
tal structure determination are given in Tables 1 and 2. CCDC
1416608 contains the supplementary crystallographic data for
the structure S1 reported in this paper. These data can be
obtained free of charge via http://www.ccdc.cam.ac.uk/conts/
retrieving.html, or from the Cambridge Crystallographic Data
Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax:
(+44) 1223 336 033; or e-mail: deposit@ccdc.cam.ac.uk.
2.7. In vitro antiamoebic assay
The synthesized compounds were screened against the HM1:
IMSS strain of E. histolytica using microdilution methodluation of quinazolin-4(3H)-one Schiﬀ base conjugates as potential antiamoebic
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Table 2 Bond lengths [A˚] and angles [] for the compound 3-
amino-2-(1H-1,2,4-triazol-1-ylmethyl)quinazolin-4(3H)-one
(S1).
Bond lengths S1
O(1)–C(5) 1.2267(17)
N(1)–C(2) 1.319(2)
N(1)–C(1) 1.350(2)
C(1)–N(2) 1.320(2)
N(2)–N(3) 1.3578(17)
C(2)–N(3) 1.330(2)
N(3)–C(3) 1.4452(17)
N(4)–N(6) 1.4128(16)
C(4)–N(5) 1.2879(18)
C(4)–N(6) 1.3775(17)
N(5)–C(11) 1.3931(18)
C(5)–N(6) 1.3943(19)
Angles S1
C(2)–N(1)–C(1) 102.34(13)
N(2)–C(1)–N(1) 115.42(14)
C(1)–N(2)–N(3) 101.72(12)
N(1)–C(2)–N(3) 110.64(14)
C(2)–N(3)–N(2) 109.88(12)
C(2)–N(3)–C(3) 128.61(12)
N(2)–N(3)–C(3) 121.51(12)
N(5)–C(4)–N(6) 123.95(13)
C(4)–N(5)–C(11) 117.08(12)
Quinazolin-4(3H)-one Schiff base conjugates as antiamoebic agents 5[46]. All the experiments were carried out in triplicate at each
concentration level and repeated thrice. E. histolytica tropho-
zoites were cultured in the TYI-S-33 growth medium in wells
of 96-well microtiter plates [47]. DMSO (40 lL) was added
to all the samples (1 mg) followed by enough culture medium
to obtain concentration of 1 mg/mL. The maximum concen-
tration of DMSO in the test did not exceed 0.1%, and at this
level no inhibition of amoebal growth had occurred. Com-
pounds were further diluted with medium to a concentration
of 0.1 mg/mL. Two fold serial dilutions were made in the wells
of 96-well microtiter plate. Each test included metronidazole
(MNZ) as the standard amoebicidal drug, control (culture
medium plus parasite) and a blank (culture medium only).(a)
NH2O
O
NHO
O
O
S
N
N
NH2
NN
N
O
S1
(d)
N
N
Scheme 1 Synthesis of quinazolin-4(3H)-one Schiff base conjugates
solution, rt. (b) 1,2,4-Triazole, DMF, K2CO3, reflux. (c) N2H4xH2O,
Please cite this article in press as: S. Tariq et al., Design, synthesis and biological eva
agents, Journal of Saudi Chemical Society (2016), http://dx.doi.org/10.1016/j.jscs.2The cell suspension was then diluted to 105 organism/mL by
adding fresh medium and 170 lL of this suspension was added
to the test and control well in the plate. Plate was sealed and
gassed for 10 min with nitrogen before incubation at 37 C
for 72 h. After incubation, the growth of amoebae in the plate
was checked with a low power microscope and the optical den-
sity of the solution in each well was determined at 490 nm with
a microplate reader. The % inhibition of amoebal growth was
calculated from the optical densities of the control and test
wells and plotted against the logarithm of the dose of the drug
tested. Linear regression analysis was used to determine the
best-fitted straight line from which the IC50 value was found.2.8. MTT assay
Cytotoxicity of the drugs was checked using MTT assay [48].
This is a colorimetric assay that measures the reduction of yel-
low 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) by mitochondrial succinate dehydrogenase. The
MTT enters the cells and passes into the mitochondria where
it is reduced to an insoluble, coloured (dark purple) formazan
product. Since reduction of MTT can only occur in metaboli-
cally active cells, the level of activity is a measure of the viabil-
ity of the cells. This formazan product is then dissolved using
organic solvents such as DMSO and absorbance was taken
using spectrophotometer. To assess the effect of the com-
pounds, HeLa cells (4000 cells/well), were plated in 96 well tis-
sue culture plates in triplicate. Each of the compounds was
added at their IC50 concentrations, as seen in E. histolytica,
as shown in Fig. 5. The cells were incubated for different time
lengths (48 h and 72 h) and cell viability assay was performed
after completion of the stipulated time intervals.3. Results and discussion
3.1. Chemistry
All the target compounds (S2–S14) were synthesized in a four
step reaction procedure as outlined in Scheme 1. The methylCl
(b)
NHO
O
N N
N
O
(c)
S2-S14
S0
N
N
O
N
N
R
. Reagents and conditions: (a) ClCH2COCl, AcOH, sat. NaOAc
EtOH, reflux. (d) RCHO, EtOH, H2SO4, reflux.
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NN
N
N
N
O
N
R
Introduction of different
Toxophoric C=N linkage of Schiff 
1,2,4 triazole:important
base enhances biological activity  
for effective antiprotozoal activity
 heteroaryl and substituted aryl
Quinazolin-4(3H)- one
Biologically active 
Linker
Figure 1 Designing of hybrid molecule.
Figure 2 ORTEP plot of the compound 3-amino-2-(1H-1,2,4-
triazol-1-ylmethyl)quinazolin-4(3H)-one (S1). All the non-hydro-
gen atoms are presented by their 50% probability ellipsoids.
Hydrogen atoms are omitted for clarity.
Figure 4 p–p stacking interactions determine the management of
molecules in the crystal packing.
6 S. Tariq et al.2-(2-chloroacetamido)benzoate (S) was synthesized from
methyl anthranilate according to the procedure described in
the literature [43]. Compound S was further reacted with
commercially available 1,2,4 triazole by nucleophilicFigure 3 Crystal packing of the compound 3-amino-2-(1H-1,2,4-tr
present in dashed black lines.
Please cite this article in press as: S. Tariq et al., Design, synthesis and biological eva
agents, Journal of Saudi Chemical Society (2016), http://dx.doi.org/10.1016/j.jscs.2substitution reaction in the presence of dimethylformamide
and K2CO3 to afford methyl 2-[(1H-1,2,4-triazol-1-ylacetyl)
amino]benzoate (S0) which reacted with hydrazine hydrate in
ethanol to give 3-amino-2-(1H-1,2,4-triazol-1-ylmethyl)quina-
zolin-4(3H)-one (S1). Further, the condensation reaction of
intermediate (S1) with various aldehydes furnished the final
compounds in good yields (S2–S14). The compounds are
stable in solid states at room temperature. All the synthesized
compounds gave satisfactory spectral data for the proposed
structures. Characteristic IR spectra showed a significant band
for the formation of compound S1 where the appearance of
strong absorptions at 3477 cm1 was assigned to the presence
of –NH. The absence of –NH stretching and presence of C‚N
stretching in the IR spectra of compounds (S2–S14) at 1597–
1614 cm1 established the conversion of –NH into its Schiff
base. The proposed structures were further confirmed by
recording the proton NMR. In the 1H NMR spectra of com-
pounds (S2–S14), N‚CH proton resonated as a singlet at d
8.62–9.51 ppm. The signals due to the aromatic protons
appeared in the expected region. The configuration (E or Z
form) of the target compounds was confirmed by 2D-
NOESY 1H NMR spectroscopy. Based on the analysis of
our 2D NOESY NMR, we have concluded that Schiff basesiazol-1-ylmethyl)quinazolin-4(3H)-one (S1). Hydrogen bonds are
luation of quinazolin-4(3H)-one Schiﬀ base conjugates as potential antiamoebic
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Table 3 In vitro antiamoebic activity of quinazolin-4(3H)-one Schiff base conjugates (S2–S14) against HM1: IMSS strain of E.
histolytica and measurement of cell viability by MTT assay.
N
N
O
NN
N
N
R
Compound code R Antiamoebic activity (IC50 ± S.D.) Cytotoxicity (IC50 ± S.D.)
48 h 72 h
S0 – 2.85 ± 0.01 N.D N.D
S1 – 1.47 ± 0.03 87.46 ± 7.11 90.23 ± 0.83
S2
Cl
1.10 ± 0.01 89.76 ± 3.05 92.86 ± 3.21
S3
Cl
0.72 ± 0.05 91.60 ± 1.31 86.43 ± 1.40
S4
Cl
1.41 ± 0.02 84.96 ± 3.95 91.96 ± 2.89
S5
NO2
0.82 ± 0.02 85.33 ± 4.06 90.46 ± 3.03
S6
O
0.96 ± 0.08 82.46 ± 3.35 93.8 ± 2.32
S7
O
O
5.01 ± 0.05 N.D N.D
S8 O 4.39 ± 0.02 N.D N.D
S9 4.12 ± 0.04 N.D N.D
S10
N
H
5.19 ± 0.02 N.D N.D
S11
S CH3 0.97 ± 0.06 89.20 ± 5.89 97.46 ± 1.11
S12
CH3
4.98 ± 0.04 N.D N.D
S13 N 5.32 ± 0.01 N.D N.D
S14
O
O
6.87 ± 0.03 N.D N.D
MNZ
N
NO2N
OH
1.80 ± 0.01 96.13 ± 1.40 96.03 ± 1.55
Quinazolin-4(3H)-one Schiff base conjugates as antiamoebic agents 7(S2–S14) exist in E configuration in DMSO solution. Also
according to the literature the compounds containing imine
bond are present in higher percentage in dimethyl D6 Sulfoxide
solution in the form of geometrical E-isomer about AC‚NPlease cite this article in press as: S. Tariq et al., Design, synthesis and biological eva
agents, Journal of Saudi Chemical Society (2016), http://dx.doi.org/10.1016/j.jscs.2double bond [49]. The structure of all the compounds was fur-
ther elucidated by mass spectral studies. All the compounds
produced C, H, and N values within 0.4% from the theoretical
values, which was acceptable.luation of quinazolin-4(3H)-one Schiﬀ base conjugates as potential antiamoebic
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8 S. Tariq et al.3.2. Single crystal structure of compound S1
ORTEP diagram for the compound 3-amino-2-(1H-1,2,4-
triazol-1-ylmethyl)quinazolin-4(3H)-one (S1) is shown in Fig. 2.
Selected bond distances and angles are given in Table 2. Atoms
C1, C2 and C3 are coplanar with the nitrogen atoms N1, N2
and N3 of triazole ring, mean deviation from the least-
squares plane being 0.0027(10) A˚. The interatomic distances
within the triazole ring are not equal, ranging from 1.319(2)
to 1.350(2) A˚, and agree with the values observed in the liter-
ature [50]. The N2–C1 bond length, 1.320(2) A˚, N3–C2 bond
length, 1.330(2) A˚ and N1–C2 bond length, 1.319(2) A˚, are sig-
nificantly shorter than the N1–C1, which is 1.350(2) A˚ and
these are longer than the average value of the lengths of the
double bonds in related triazole thiones [1.300(2) A˚; Cam-
bridge. Structural Database, version 5.26; ConQuest, version
3.6] [50]. This is attributed to the presence of a non uniform
delocalization between the lone pair on nitrogen atoms and
the next atoms in the triazole ring. The N3–C3 bond length
is 1.4452(17) A˚ similar to other N–C bonds in triazole substi-
tuted rings [51]. The presence of intermolecular forces between
the rings of quinazoline group determines the crystal packing.
Intermolecular hydrogen bonds between the amine group and
oxo group of two different quinazoline groups determine
the structure of the compound. p–p stacking interactions
between the rings establish the link between frameworks and
determine the structure in layers. The distances between p
clouds of the centroids in the rings of quinazoline groups are:
dc1–c2 = 3.641 A˚ [c1 (C4A–C5A–C6A–C11A–N5A–N6A) and
c2 (C6C–C7C–C8C–C9C–C10C–C11C)] and repeated for
other centroids (Figs. 3 and 4).3.3. Evaluation of biological activities
3.3.1. Antiamoebic activity
To scrutinize the antiamoebic potential of the synthesized
compounds (S1–S14), they were screened against HM1: IMSS
strain of E. histolytica using metronidazole as reference amoe-
bicidal drug which had a 50% inhibitory concentration (IC50)
1.80 lM in our experiments. All the experiments were carried
out in triplicate at each concentration level and repeated thrice.
Cytotoxicity of the compounds having IC50 value less than0 
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Figure 5 Assessment of viability of HeLa cells in response to compou
in triplicate for 48 h and 72 h and treated with the compounds. Cells t
completion of stipulated time intervals and processed. Absorbance wa
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agents, Journal of Saudi Chemical Society (2016), http://dx.doi.org/10.1016/j.jscs.2metronidazole was assessed by MTT assay on human cervical
cancer HeLa cell line. The results of antiamoebic activity and
cytotoxicity are summarized in Table 3. Antiamoebic results
suggest that the intermediate compound S1 (IC50 = 1.47 lM)
incorporating both quinazolin-4(3H)-one and 1,2,4-triazole
ring was a more potent amoebicidal agent than S0
(IC50 = 2.85 lM) incorporating only 1,2,4-triazole. Further-
more compound S1 had lower IC50 values than MNZ. We fur-
ther synthesized Schiff base conjugates. All the final
compounds have IC50 values in the range 0.72–6.87 lM. Out
of the thirteen synthesized compounds, six compounds: S2
(IC50 = 1.10 lM), S3 (IC50 = 0.72 lM), S4 (IC50 = 1.41
lM), S5 (IC50 = 0.82 lM), S6 (IC50 = 0.96 lM) and S11
(IC50 = 0.97 lM) were found to exhibit better antiamoebic
activity than intermediate compound S1 and the standard drug
MNZ (IC50 = 1.80 lM). Compound S3 having weak deacti-
vating chloro group at meta position of phenyl ring, exhibited
promising activity (IC50 = 0.72 lM) than compounds S4
(IC50 = 1.41 lM) and S2 (IC50 = 1.10 lM), where the chloro
group is present at para and ortho positions respectively. Intro-
duction of strong deactivating nitro group S5 (IC50 = 0.82
lM), at para position of phenyl ring exerts significant
inhibitory activity, whereas the presence of strong activating
methoxy group S8 (IC50 = 4.39 lM), and N,N dimethylamine
S13 (IC50 = 5.32 lM) group at the same position exhibited
less activity. Weak activating methyl group which increases
the electron density through hyperconjugation to the aromatic
ring, when present at ortho position, S12 (IC50 = 4.98 lM)
showed less activity than the unsubstituted phenyl ring, S9
(IC50 = 4.12 lM). However, the activity decreased in com-
pound S7 by inserting two methoxy groups at positions 2
and 5 of the phenyl ring (IC50 = 5.01 lM). The study of struc-
ture activity relationships of the synthesized compounds indi-
cate that the replacement of substituted phenyl ring of Schiff
base with bulky piperonal S14 (IC50 = 6.87 lM) and indole
ring S10 (IC50 = 5.19 lM) resulted in the dramatic decrease
in the activity due to the reduced aromaticity or the bulky nat-
ure of the group which might be imposing steric hindrance.
However, the presence of heteroaromatic ring like thiophene
S11 (IC50 = 0.97 lM) and furan S6 (IC50 = 0.96 lM) was
helpful in increasing the activity of the compounds. Thus from
the above discussion it can be concluded that compound S3
seems to be the most potent of all the compounds screened.48h 72h
r treatment
.1 µM S3: 0.72 µM S4: 1.41 µM
0.97 µM MNZ: 1.8 µM
nds S1, S2, S3, S4, S5, S6 and S11 at their IC50. Cells were plated
reated with DMSO are used as the control. MTT was added after
s taken at 570 nm.
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Quinazolin-4(3H)-one Schiff base conjugates as antiamoebic agents 93.3.2. Cytotoxicity
To assess the effect of the compounds on cervical cancer cell
line, HeLa cells (4000 cells/well), were plated in 96 well tissue
culture plates in triplicate. Each of the compounds was added
at the concentrations of their IC50 as seen in E. histolytica, as
shown in Fig. 5. The cells were incubated for different time
lengths (48 h and 72 h) and cell viability assay was performed
after completion of the stipulated time intervals. As seen in
Table 3, when cells were treated with compounds S1, S2, S4,
S5, S6 and S11 at their IC50, more than 90% cell viability
was observed while S3 resulted in cell viability of 86.4%. Thus
above results showed that there is no significant reduction in
cell viability of HeLa cells on treatment with the above men-
tioned compounds.
4. Conclusion
To conclude, this paper describes the synthesis and biological
evaluation of quinazolin-4(3H)-one Schiff base conjugates as
inhibitors of E. histolytica. The in vitro study suggested that
some quinazolin-4(3H)-one derivatives exhibited potent amoe-
bicidal activity than the standard drug. It was also observed
that the intermediate compound S1 incorporating both
quinazolin-4(3H)-one and 1,2,4-triazole ring displayed better
activity (IC50 = 1.47 lM) than S0. Therefore, we hypothesized
that the combination of two biologically important hetero-
cyclic scaffolds, quinazolin-4(3H)-one and 1,2,4-triazole in
S1, is expected to exhibit synergistic effects to display anti-
amoebic activity. As the basic skeleton of compound S1
(IC50 = 1.47 lM) is entirely different from S0 (IC50 =
2.85 lM), it can be concluded that the entire molecular-
skeleton of the particular compound is concerned with its
IC50 value and therefore, responsible for its antiamoebic activ-
ity. The structure activity relationship (SAR), of the com-
pounds (S2–S14) shared three common features: the presence
of 1,2,4-triazole ring, azomethine linkage and quinazolin-4
(3H)-one ring (Fig. 1) but differ in their corresponding anti-
amoebic activity. It may be due to the different substituents
on the phenyl ring of Schiff bases. The presence of heteroaro-
matic rings like furan and thiophene, electron withdrawing
groups like nitro group on meta position and weakly deactivat-
ing group like chloro on ortho, meta and para position of the
phenyl ring of Schiff bases generally increase the antiamoebic
activity. Also, the entire molecular-skeleton of the particular
compound is responsible for its antiamoebic activity. Out of
all the screened compounds only seven compounds (S1, S2,
S3, S4, S5, S6 and S11) were found to be better inhibitors of
growth E. histolytica than the reference drug metronidazole.
MTT assay revealed that there is no significant reduction in
cell viability of HeLa cells on treatment with the above men-
tioned compounds at their IC50. Thus these compounds show
low cytotoxicity. In the present work we have adopted simple
synthetic strategy to design target motifs which will encourage
further advancement in the synthesis of novel derivatives to
conduct comprehensive evaluation of their biological activities.
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